SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: jaci hartman who wrote (492)5/4/1998 11:03:00 AM
From: Haolin Ni  Read Replies (3) | Respond to of 2135
 
ENMD will be less than $20 after one year.

Look at the GERN, Two papers published at the Sciences.

A lot of the company reported good cancel cure drugs in mice, almost none of them can be used in humans.

Good luck to all dare to play this one.



To: jaci hartman who wrote (492)5/4/1998 11:22:00 AM
From: StockDoc  Read Replies (4) | Respond to of 2135
 
If the drug works in man as preliminary clinical data now suggest (it's coming, watch out), and they can manufacture, it should be above 100 next year.
StockDoc



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News